|Bid||165.00 x 1000|
|Ask||167.88 x 800|
|Day's range||159.91 - 169.26|
|52-week range||121.32 - 464.00|
|Beta (5Y monthly)||-0.70|
|PE ratio (TTM)||5.29|
|Earnings date||09 Nov 2021|
|Forward dividend & yield||2.11 (1.33%)|
|Ex-dividend date||02 Jun 2022|
|1y target est||320.42|
European Commission authorizes a booster dose of AstraZeneca's (AZN) COVID-19 vaccine and approves Merck (MRK) and Roche's (RHHBY) oncology drugs for expanded use.
AstraZeneca's (AZN) third/booster dose of its COVID-19 vaccine gets authorized in Europe for use in adults, both for homologous and heterologous use.
Ocugen (OCGN) gets respite after the FDA lifts the clinical hold on the company's phase II/III study, OCU-002, for Covaxin (BBV152).